Chemical Property of Suplatast Tosilate
Chemical Property:
- Appearance/Colour:white or off-white crystals
- Melting Point:84-87 °C
- PSA：158.67000
- LogP:3.72220
- Storage Temp.:Store at RT
- Solubility.:DMSO: >20mg/mL
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:10
- Exact Mass:499.16984474
- Heavy Atom Count:33
- Complexity:500
- Purity/Quality:
-
99% *data from raw suppliers
Suplatast Tosylate *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O.CC1=CC=C(C=C1)S(=O)(=O)[O-]
- Recent EU Clinical Trials:A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis
- Recent NIPH Clinical Trials:A prospective, randomized, single- blind, controlled study to investigate the effect of suplatast tosilate on early- stage idiopathic pulmonary fibrosis
-
Description
Suplatast tosylate is a unique dimethylsulfonium salt marketed in Japan
for the treatment of bronchial asthma, atopic dermatitis and allergic rhinitis. Suplatast
tosylate is a potent inhibitor of IgE synthesis without suppressing IgM and IgG. The
mechanism of action for suplatast tosylate is thought to be via the inhibition of
interleukin-4 and interleukin-6 production by T-cells at the gene level. In allergic
patients, suplatast tosylate markedly improved clinical symptoms which correlated with
a significant decrease in serum IgE antibody levels. Suplatast is an antiallergic agent. It inhibits IL-4 and IL-5 production in conalbumin-stimulated D10.G4.1 murine T helper 2 (Th2) cells in a concentration-dependent manner. Suplatast (100 mg/kg) inhibits ovalbumin-induced increases in eosinophil and total cell numbers, as well as IL-4, IL-5, and IL-13, but not IFN-γ, levels in bronchoalveolar lavage fluid (BALF) in an ovalbumin-sensitized mouse model of asthma. It also inhibits ovalbumin-induced increases in ovalbumin-specific IgE in serum and bronchial hyperresponsiveness to methacholine in the ovalbumin-sensitized mouse model of asthma.
-
Uses
Suplatast Tosylate is an antiallergic drug. Suplatast Tosylate inhibits antigen-induced histamine release from mast cells as well as IgE antibody formation. Suplatast Tosylate suppresses interleukin (IL)-4 release from T cells, however in human peripheral basophils, Suplatast Tosylate inhibited the antigen-induced release of IL-13 but not IL-4. Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.
